SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated.
As a result, the board of directors will reassess the Company’s strategic alternatives, including out-licensing, merger and acquisition opportunities (including reverse mergers), the sale of assets and technologies, and winding down operations, among other potential transactions.
As of February 26, 2025, the Company had approximately $3.9 million in cash. The Company’s cash runway is expected to extend through late Q2 2025.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events …
